



T | +61 3 5339 0704
E | info@idxgroup.com.au

Suite 9.02, Level 9,
45 William Street
Melbourne Vic 3000

www.integraldiagnostics.com.au

ASX & MEDIA RELEASE

Completion of distribution of Retail Offer Booklet

Not for release or distribution in the United States

1 March 2022, Melbourne

Integral Diagnostics Limited (ASX:IDX) confirms that:

1. the retail entitlement offer booklet ("**Retail Offer Booklet**") and personalised entitlement and acceptance forms regarding the retail component of the 1 for 7.75 pro rata accelerated non-renounceable entitlement offer ("**Entitlement Offer**") ("**Retail Entitlement Offer**") of new shares in IDX ("**New Shares**"), which was announced on Wednesday, 23 February 2022, were distributed today to Eligible Retail Shareholders (as defined in the Retail Offer Booklet) of IDX who have a registered address in Australia and New Zealand and who have nominated to receive documents from IDX by electronic means; and
2. other Eligible Retail Shareholders of IDX who have a registered address in Australia and New Zealand, were despatched a letter notifying them of the Retail Entitlement Offer and providing instructions on how to participate in the Retail Entitlement Offer.

Retail Entitlement Offer

The Retail Entitlement Offer opened today, Tuesday, 1 March 2022 and is expected to close at 5.00pm (Melbourne time) on Monday, 14 March 2022.

Eligible Retail Shareholders should carefully read the Retail Offer Booklet for further details about the Retail Entitlement Offer.

If you have any questions regarding the Entitlement Offer, please contact the IDX Offer Information Line on 1300 850 505 (within Australia) or +61 3 9415 4000 (outside Australia) between 8.30am and 5.00pm (Melbourne time) on Monday to Friday, before the Retail Entitlement Offer closes. If you have any further questions, you should contact your stockbroker, solicitor, accountant or other professional adviser.

For further details contact

Integral Diagnostics

Kirsty Lally
M: 0402 094 569

Authorised for lodgement by the Managing Director and CEO, Dr Ian Kadish

About IDX:

Integral Diagnostics (IDX) is a leading provider of medical imaging services across Australia and New Zealand. The Company provides state of the art diagnostic services to patients and their referrers at 71 radiology clinics, including 29 comprehensive sites. IDX employs some of Australasia's leading radiologists and nuclear medicine specialists in a unique medical leadership model that ensures quality patient care, service and access. Good medicine is good business. For more information, please visit www.integraldiagnostics.com.au/.

Important Notice

NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES

This announcement is not financial product advice and has not taken into account your objectives, financial situation or needs. This announcement has been prepared for release in Australia. This announcement does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or in any jurisdiction in which such an offer would be illegal. The New Shares have not been, nor will be, registered under the U.S. Securities Act of 1933 (the "Securities Act") or the securities laws of any state or other jurisdiction of the United States. Accordingly, the New Shares may not be offered or sold, directly or indirectly, to any person in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable U.S. state securities laws.